For Immediate Release

e-CRO forms network with five European CROs, Beacon Bioscience

AUSTIN, Texas - June 10, 2003 — ResearchPoint, a rapidly expanding e-CRO, announced the formation of the ResearchPoint Global Network (RPGN), composed of five premier European CROs, coupled with ResearchPoint and its U.S. partner, Beacon Bioscience. RPGN will provide clients with integrated and expanded development services within Europe and North America.

In addition to ResearchPoint, RPGN includes TheraGenesis, headquartered in Karlsrühe, Germany; Russian Clinical Trials, Inc. (RCT), St. Petersburg, Russia; CamClin, Cambridge, U.K.; North Sweden Clinical Research Institute, located in Umeå, Sweden; and Beacon Bioscience headquartered in Doylestown, Pennsylvania. Each company functions as a stand-alone organization, but has entered into a structured partnership offering expanded services to their clients through the members of this network.

"In response to customers' requests, we have completed this expansion one full year ahead of schedule. We are excited about this development, as are our current customers," said John Farinacci, CEO of ResearchPoint. "This structure optimizes and expands our ability to offer competitively-priced, value-added services on a global basis."

Carol Breslauer, Vice President of Operations at ResearchPoint, and Farinacci have successfully built similar corporate collaborations in their previous affiliations. "We have leveraged long-standing professional relationships with groups known for their quality and with whom we had prior experience, to form this network. We have found these partnerships, when structured correctly, are extraordinarily productive," said Breslauer.

"The reputation and global experience of the senior management at ResearchPoint was what attracted Russian Clinical Trials to become a partner of the RPGN," said Sumit Seth, Director, Business Development, RCT.

"The senior management of TheraGenesis and ResearchPoint have a project operations relationship stretching more than a decade," commented Udo Hesse, Managing Director of TheraGenesis. "Our team has produced results that are well-acknowledged by our pharmaceutical, biotechnology and medical device customers. The formalization of our collaboration is a natural extension of our joint expertise, capabilities and commitment."

"Our partners in this network give us substantially expanded coverage in order to meet the needs of our clients who are demanding broader and more full-service capabilities," noted Elisabeth Karlsson, Managing Director of North Sweden Clinical Research Institute.

Beacon Bioscience's CEO, Ted Gastineau, stated "The longstanding working relationship that we have had with the senior management team at ResearchPoint was the initial attraction to becoming a partner with RPGN. The global span of this network complements our internal technology initiatives relative to remote medical imaging data access and review from various locations around the world. The partners in this network allow us to provide our clients with increased access to the group's unique services and capabilities."

ResearchPoint is an e-CRO, which provides traditional and electronically enhanced services to the pharmaceutical, biomedical and medical device industries. ResearchPoint technology initiatives focus on communication and training as aids to accelerate and improve the quality of its clinical programs.

For more information, please visit www.researchpoint.com or contact David Reichert, at 512-343-1092 or dreichert@researchpoint.com.